$PLUS

Callies John E sold $44K of PLUS

Callies John E sold 500 shares of EPLUS INC (PLUS) at an average of $88.09 ($88.08–$88.85) across 2 trades on 2026-08-14.

Original reporting
SEC EDGAR · Callies John E
Published Aug 17, 2026, 8:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PLUS
Neutral
medium confidence
Mentioned
$PLUS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PLUSNeutralLow
01

Why it matters

A director open-market sale of 500 shares is disclosed, but there is no accompanying company news (earnings, guidance, deals, or regulatory actions).

02

Market read

Traders may note insider selling as a minor sentiment input, but the filing alone does not provide a new fundamental catalyst.

03

What to watch

The article does not state motivations, tax considerations, or whether other insiders are buying; it also provides only the sale size, not broader ownership changes.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-17 after trades dated 2026-08-14

Background

The article is an SEC Form 4 insider transaction disclosure for EPLUS Inc (PLUS).

Company-level read

Ticker impact

$PLUSNeutralMedium confidence
Context

EPLUS director John E Callies filed a Form 4 selling 500 shares of PLUS for about $44,043 at ~$88.09-$88.85 per share.

Expected impact

Low near-term impact; any reaction is likely limited to short-lived sentiment.

Evidence & confidence

The filing is a disclosed open-market sale by a director, but it does not include new company performance, guidance, or material corporate events.

Market effects

No sector-level implications; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for diversification or liquidity needs, so the signal may be overstated versus the lack of any fundamental change.

Key entities

  • EPLUS Inc

    Company whose insider transaction is disclosed on Form 4.

  • John E Callies

    Director who sold 500 shares of PLUS on 2026-08-14.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CDWMedAI 8/10

Q2 Earnings Outperformers: CDW (NASDAQ:CDW) And The Rest Of The IT Distribution & Solutions Stocks

CDW, ePlus, TD SYNNEX, and ScanSource reported Q2 earnings. CDW (-6%) and ePlus (-10.5%) saw stock declines, while ScanSource (+5.5%) rose. TD SYNNEX (-10.5%) reported strong revenue growth but also fell. ePlus reported flat revenue but beat EPS estimates. ScanSource had the largest analyst estimate beat. TD SYNNEX reported $19.57B revenue, up 31% YoY, and beat EPS estimates and guidance.

$PLUSMed

Plus500 increases buybacks as US growth continues

Plus500 said it will increase shareholder returns via buybacks alongside its half-year results. The company reported double-digit revenue growth year over year and Ebitda up 1% to $188mn. It attributed a lower Ebitda margin (45% to 41%) to higher marketing spend to attract new customers, while expanding in US futures.

$PLUSMedAI 8/10

Why ePlus (PLUS) Shares Are Plunging Today

ePlus (NASDAQ: PLUS) shares fell about 5% after the company reported Q2 2026 results. Revenue rose 1.9% year over year to $649.1 million and adjusted EPS was $1.28, both above Wall Street estimates. Despite the beat, investors focused on declining adjusted operating and free cash flow margins and a forecast of about 2% full-year EPS growth. Shares later traded near $92.31.